CME/CE

This activity focuses on optimizing first-line treatment strategies for patients with chronic lymphocytic leukemia (CLL). Drs. William Wierda and Matthew Davids discuss key distinctions between continuous BTK inhibitor therapy and time-limited venetoclax-based regimens, while highlighting considerations such as comorbidities, toxicities, IGHV status, and TP53 aberrations. They examine recent and emerging data from trials including CLL17, AMPLIFY, and BRUIN CLL-313, as well as novel agents. The conversation underscores the importance of personalized therapy selection in frontline CLL care.

For ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event, cardiologists continue to face a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Despite adherence to quadruple guideline-directed medical therapy (GDMT) and device support, these “stable,” guideline-treated patients carry residual risk for CV death. Recent evidence shows that the addition of soluble guanylate cyclase (sGC) stimulators provides significant reductions in CV death and all-cause mortality, particularly in individuals with moderately elevated NT-proBNP (≤6,000 pg/mL). However, cardiologists often underestimate risk in these ambulatory patients and may hesitate to add therapies when GDMT appears to be working well. Our experts break down a case to illustrate how and when to employ recent data regarding the use of additional sGC in appropriate patients with HFrEF.

This online educational activity equips clinicians with up-to-date, practice-changing insights from SABCS 2025. Experts review pivotal data across early-stage and metastatic breast cancer, including advances in HER2- and TROP2-directed ADCs, and discuss how these findings can meaningfully inform treatment selection. Participants will learn how to apply new evidence to expand therapeutic options, improve patient outcomes, and navigate emerging safety and quality of life considerations.

This online educational activity provides clinicians with an in-depth review of the latest findings in head and neck squamous cell carcinoma (HNSCC) from ESMO 2025, highlighting advances in both resectable locally advanced and recurrent/metastatic disease. Faculty experts first explore new data on perioperative and adjuvant immunotherapy in locally advanced disease then discuss novel targeted and immunotherapy-based approaches that are showing promise in recurrent/metastatic disease. Safety profiles, patient-reported outcomes, and multidisciplinary considerations are addressed to support thoughtful integration of these therapies into real-world practice. These insights reinforce evolving strategies designed to enhance outcomes for patients across the full HNSCC spectrum.

This educational activity examines the growing evidence supporting bispecific antibodies in earlier treatment lines of multiple myeloma. Experts discuss the rationale for upstream use of bispecific antibodies and review key data from pivotal trials highlighting the evolving role for bispecific antibodies as early-line treatment. Practical considerations such as monitoring and managing adverse events associated with bispecific antibodies are discussed to guide real-world adoption. Together, these insights help clinicians integrate emerging evidence into practice to optimize patient outcomes as bispecific antibodies move earlier in the myeloma treatment paradigm.

On March 5, 2026, the FDA approved teclistamab plus daratumumab for patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.